Table of Contents
The $1.25 million grant builds on Beken Bio’s successful SBIR Phase I award and represents an important next step in the development and validation of the company’s diagnostic technology, marking a significant milestone in the Beken Bio NSF Phase II grant announcement.
What the Beken Bio NSF Phase II Grant Will Fund
Beken Bio is developing a liquid biopsy that uses a simple blood test to identify extracellular vesicles, tiny cancer-related particles that can appear in the bloodstream. The technology is designed to detect ovarian cancer earlier and in a less invasive way than current diagnostic approaches.
Leadership’s Reaction to This Grant
“This award represents an inflection point for Beken Bio,” said Christopher Millan, PhD, co-founder and CEO. “Over the past several years we’ve built the scientific foundation for our ovarian cancer detection platform. Phase II funding allows us to put that technology to the test in real patients across Louisiana, work toward reimbursement and commercialization, and begin expanding our platform to a second indication in lung cancer. It’s an exciting step toward building a company that can fundamentally change how cancers are detected.”
The Clinical Problem Behind the Beken Bio NSF Phase II Grant
Its work addresses a major unmet need in gynecologic oncology: accurately distinguishing malignant from benign ovarian masses before surgery. The company’s technology seeks to provide objective molecular information about the signs of cancer, ensuring patients at highest risk for ovarian cancer reach specialist care promptly.
How the Underlying Technology Works
Beken Bio’s proprietary 3D REVEAL engine captures tumor-derived extracellular vesicles from routine blood draws and uses machine learning to pinpoint cancer-specific signatures, giving clinicians an objective, molecular basis for triaging patients rather than relying solely on imaging or symptom presentation alone.
Building on Earlier Momentum Ahead of the Beken Bio NSF Phase II Grant
The Phase II award also marks continued growth in New Orleans. The company recently expanded its NOBIC laboratory operations to support its clinical and commercial development. The lab is designed to support regulatory and operational milestones as Beken Bio works toward commercialization of its first diagnostic product.
Why the CLIA-Certified Lab Matters
Establishing a CLIA-certified facility at NOBIC represents a critical prerequisite for offering the ovarian cancer test as an actual clinical service, since Clinical Laboratory Improvement Amendments certification is legally required before any diagnostic test can be used to guide patient care decisions in the U.S.
The Broader Funding and Clinical Partner Network Behind Beken Bio
Beken Bio previously secured a National Science Foundation SBIR Phase I award and clinical collaboration with gynecologic oncologists at LCMC Health and Ochsner Medical Centers, giving the company established relationships with Louisiana health systems to evaluate the test in real clinical settings. Tulane Ventures has invested $125,000 to support clinical studies, hiring and equipment, and the company has also drawn seed support from Boot64, the New Orleans BioFund, and 1834 Ventures, with the Community Development Venture Capital Alliance co-investing alongside the BioFund on the CLIA lab build-out.
Why This Funding Mix Signals Strong Local and National Confidence
This combination of federal SBIR funding, university-affiliated venture capital, and national impact investors reflects a layered financing strategy that has allowed Beken to advance simultaneously on scientific validation, clinical infrastructure, and commercial readiness rather than depending on a single funding source.
What the Beken Bio NSF Phase II Grant Means Going Forward
With Phase II funding now secured, Beken Bio’s stated plan to test its technology in real patients across Louisiana while simultaneously pursuing reimbursement pathways and a second lung cancer indication suggests the company is moving toward a multi-product commercialization strategy rather than focusing narrowly on its original ovarian cancer application. Given ovarian cancer’s status as the deadliest gynecologic cancer in the United States, largely due to late-stage diagnosis, a validated blood-based screening tool distinguishing malignant from benign masses could meaningfully shift how quickly high-risk patients reach specialist care.
What to Watch Going Forward
As Beken Bio moves into real-patient testing across Louisiana health systems, industry observers will likely watch for early clinical validation data demonstrating the 3D REVEAL platform’s accuracy in distinguishing malignant from benign ovarian masses. Given the company’s stated ambition to expand into lung cancer as a second indication, the success of this Beken Bio NSF Phase II grant-funded clinical work in ovarian cancer may serve as a proof-of-concept that shapes investor and regulatory confidence in the platform’s broader applicability across additional cancer types.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
